Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

• Published in: The New England journal of medicine Vol. 377; no. 16; pp. 1525 - 1536
• Main Authors: Gladman, Dafna, Rigby, William, Azevedo, Valderilio F, Behrens, Frank, Blanco, Ricardo, Kaszuba, Andrzej, Kudlacz, Elizabeth, Wang, Cunshan, Menon, Sujatha, Hendrikx, Thijs, Kanik, Keith S
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 19-10-2017
• Subjects: Administration, Oral; Adult; Alanine; Alanine transaminase; Alanine Transaminase - blood; Antirheumatic Agents - therapeutic use; Arthritis; Arthritis, Psoriatic - drug therapy; Aspartate Aminotransferases - blood; Cerebral infarction; Cytokines; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; Drug therapy; Drug Therapy, Combination; Enzyme inhibitors; Female; Herpes zoster; Humans; Inhibitor drugs; Ischemia; Janus kinase; Janus Kinases - antagonists & inhibitors; Male; Middle Aged; Myocardial infarction; Patients; Piperidines - administration & dosage; Piperidines - adverse effects; Piperidines - therapeutic use; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Psoriasis; Psoriatic arthritis; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Pyrroles - administration & dosage; Pyrroles - adverse effects; Pyrroles - therapeutic use; TNF inhibitors; Treatment Failure; Tumor necrosis factor; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor necrosis factor-TNF
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1615977

Treatment of psoriatic arthritis with the oral Janus kinase inhibitor tofacitinib for 3 months was more effective than placebo in reducing joint manifestations, as determined by the American College of Rheumatology 20% response rate, but was associated with herpes infections.